Skip to main content

Advertisement

Table 2 Clinical characteristics of bone marrow metastatic neuroblastoma patients according to MYCN and 11q23 statuses

From: Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification

Variable MYCN status [cases (%)] P value* 11q23 status [cases (%)] P value*
Amplified Normal Deleted Normal
Total 12 89   40 61  
Sex
 Male 7 (58.3) 50 (56.2) 0.536 24 (60.0) 33 (54.1) 0.682
 Female 5 (41.7) 39 (43.8)   16 (40.0) 28 (45.9)  
Age (months)
 < 18 4 (33.3) 12 (13.5) 0.095 2 (5.0) 14 (23.0) 0.024
 ≥ 18 8 (66.7) 77 (86.5)   38 (95.0) 47 (77.0)  
Primary tumor site
 Abdomen 12 (100.0) 76 (85.4) 0.436 33 (82.5) 55 (90.2) 0.339
 Thorax 0 (0) 12 (13.5)   6 (15.0) 6 (9.8)  
 Neck 0 (0) 1 (1.1)   1 (2.5) 0 (0)  
LDH (IU/L)
 < 1500 1 (8.3) 78 (87.6) <0.001 32 (80.0) 47 (77.0) 0.808
 ≥ 1500 11 (91.7) 11 (12.4)   8 (20.0) 14 (23.0)  
NSE (ng/mL)
 < 370 1 (8.3) 59 (66.3) < 0.001 21 (52.5) 39 (63.9) 0.302
 ≥ 370 11 (91.7) 30 (33.7)   19 (47.5) 22 (36.1)  
Event
 No 1 (8.3) 48 (53.9) 0.004 16 (40.0) 33 (54.1) 0.118
 Yes 11 (91.7) 41 (46.1)   24 (60.0) 28 (45.9)  
  1. MYCN the v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog, LDH lactate dehydrogenase, NSE neuron-specific enolase
  2. * The χ2 test was used for statistical analysis